Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

Authors: Ren-Wen Huang, Yin-Kai Chao, Yu-Wen Wen, Hsien-Kun Chang, Chen-Kan Tseng, Sheng-Chieh Chan, Yun-Hen Liu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Backgrounds

In this study, we evaluated the factors associated with a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).

Methods

Pre-nCRT parameters in ESCC patients treated between 1999 and 2006 were analyzed to identify predictors of pCR. All patients received 5-fluorouracil/cisplatin-based chemotherapy and external beam radiation followed by scheduled esophagectomy. Variables were analyzed using univariate and multivariate analyses with pCR as the dependent variable. Estimated pCR rate was calculated with a regression model.

Results

Fifty-nine (20.9%) of 282 patients achieved pCR. Univariate analysis identified four patient factors (age, smoking status, drinking history and hypertension), one pre-nCRT parameter (tumor length) as significant predictors of pCR (all P <0.05). On multivariate analysis, tumor length ≤3 cm (favorable, odds ratio (OR): 4.85, P = 0.001), patient age >55 years (favorable, OR: 1.95, P = 0.035), and being a non-smoker (favorable, OR: 3.6, P = 0.003) were independent predictors of pCR. The estimated pCR rates based on a logistic regression including those three predictors were 71%, 35 to approximately 58%, 19 to approximately 38%, and 12% for patients with 3, 2, 1 and 0 predictors, respectively.

Conclusion

Age, smoking habit and tumor length were important pCR predictors. These factors may be used to predict outcomes for ESCC patients receiving nCRT, to develop risk-adapted treatment strategies, and to select patients who could participate in trials on new therapies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med. 2003, 349: 2241-2252. 10.1056/NEJMra035010.CrossRefPubMed Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med. 2003, 349: 2241-2252. 10.1056/NEJMra035010.CrossRefPubMed
2.
go back to reference Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996, 335: 462-467. 10.1056/NEJM199608153350702.CrossRefPubMed Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996, 335: 462-467. 10.1056/NEJM199608153350702.CrossRefPubMed
3.
go back to reference Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.CrossRefPubMed
4.
go back to reference Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005, 23: 4330-4337. 10.1200/JCO.2005.05.017.CrossRefPubMed Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005, 23: 4330-4337. 10.1200/JCO.2005.05.017.CrossRefPubMed
5.
go back to reference Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C: Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009, 87: 392-398. 10.1016/j.athoracsur.2008.11.001. discussion 398–399PubMedCentralCrossRefPubMed Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C: Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009, 87: 392-398. 10.1016/j.athoracsur.2008.11.001. discussion 398–399PubMedCentralCrossRefPubMed
6.
go back to reference Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010, 17: 1159-1167. 10.1245/s10434-009-0862-1.CrossRefPubMed Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010, 17: 1159-1167. 10.1245/s10434-009-0862-1.CrossRefPubMed
7.
go back to reference Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL: Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012, 19: 1678-1684. 10.1245/s10434-011-2078-4.CrossRefPubMed Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL: Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012, 19: 1678-1684. 10.1245/s10434-011-2078-4.CrossRefPubMed
8.
go back to reference Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005, 104: 2365-2372. 10.1002/cncr.21439.CrossRefPubMed Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005, 104: 2365-2372. 10.1002/cncr.21439.CrossRefPubMed
9.
go back to reference Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, Friess H, Theisen J: Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010, 16: 330-337. 10.1158/1078-0432.CCR-09-1673.CrossRefPubMed Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, Friess H, Theisen J: Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010, 16: 330-337. 10.1158/1078-0432.CCR-09-1673.CrossRefPubMed
10.
go back to reference Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, O'Byrne KJ, Sheils OM, Hollywood D, Reynolds JV: Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009, 250: 729-737. 10.1097/SLA.0b013e3181bce7e1.CrossRefPubMed Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, O'Byrne KJ, Sheils OM, Hollywood D, Reynolds JV: Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009, 250: 729-737. 10.1097/SLA.0b013e3181bce7e1.CrossRefPubMed
11.
go back to reference Duong C, Greenawalt DM, Kowalczyk A, Ciavarella ML, Raskutti G, Murray WK, Phillips WA, Thomas RJ: Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol. 2007, 14: 3602-3609. 10.1245/s10434-007-9550-1.CrossRefPubMed Duong C, Greenawalt DM, Kowalczyk A, Ciavarella ML, Raskutti G, Murray WK, Phillips WA, Thomas RJ: Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol. 2007, 14: 3602-3609. 10.1245/s10434-007-9550-1.CrossRefPubMed
12.
go back to reference Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA: Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006, 24: 259-267.CrossRefPubMed Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA: Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006, 24: 259-267.CrossRefPubMed
13.
go back to reference Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002, 86: 552-557. 10.1038/sj.bjc.6600129.PubMedCentralCrossRefPubMed Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer. 2002, 86: 552-557. 10.1038/sj.bjc.6600129.PubMedCentralCrossRefPubMed
14.
go back to reference Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004, 10: 3794-3799. 10.1158/1078-0432.CCR-03-0079.CrossRefPubMed Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res. 2004, 10: 3794-3799. 10.1158/1078-0432.CCR-03-0079.CrossRefPubMed
15.
go back to reference Hothorn T, Hornik K, Zeileis A: Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006, 15: 651-674. 10.1198/106186006X133933.CrossRef Hothorn T, Hornik K, Zeileis A: Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006, 15: 651-674. 10.1198/106186006X133933.CrossRef
16.
go back to reference Oze I, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I, Tamakoshi A, Sasazuki S, Inoue M, Tsugane S, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan: Cigarette smoking and esophageal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2012, 42: 63-73. 10.1093/jjco/hyr170.CrossRefPubMed Oze I, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I, Tamakoshi A, Sasazuki S, Inoue M, Tsugane S, Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan: Cigarette smoking and esophageal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2012, 42: 63-73. 10.1093/jjco/hyr170.CrossRefPubMed
17.
go back to reference Shitara K, Matsuo K, Hatooka S, Ura T, Takahari D, Yokota T, Abe T, Kawai H, Tajika M, Kodaira T, Shinoda M, Tajima K, Muro K, Tanaka H: Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci. 2010, 101: 1001-1006. 10.1111/j.1349-7006.2009.01466.x.CrossRefPubMed Shitara K, Matsuo K, Hatooka S, Ura T, Takahari D, Yokota T, Abe T, Kawai H, Tajika M, Kodaira T, Shinoda M, Tajima K, Muro K, Tanaka H: Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci. 2010, 101: 1001-1006. 10.1111/j.1349-7006.2009.01466.x.CrossRefPubMed
18.
go back to reference Sundelof M, Lagergren J, Ye W: Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer. 2008, 44: 1566-1571. 10.1016/j.ejca.2008.04.002.CrossRefPubMed Sundelof M, Lagergren J, Ye W: Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer. 2008, 44: 1566-1571. 10.1016/j.ejca.2008.04.002.CrossRefPubMed
19.
go back to reference Nozoe T, Korenaga D, Kabashima A, Sugimachi K: Smoking-related increase of O(6)-methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. Cancer Lett. 2002, 184: 49-55. 10.1016/S0304-3835(02)00188-X.CrossRefPubMed Nozoe T, Korenaga D, Kabashima A, Sugimachi K: Smoking-related increase of O(6)-methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. Cancer Lett. 2002, 184: 49-55. 10.1016/S0304-3835(02)00188-X.CrossRefPubMed
20.
go back to reference Ohba T, Kometani T, Shoji F, Yano T, Yoshino I, Taguchi K, Kuraoka I, Oda S, Maehara Y: Expression of an X-family DNA polymerase, pol lambda, in the respiratory epithelium of non-small cell lung cancer patients with habitual smoking. Mutat Res. 2009, 677: 66-71. 10.1016/j.mrgentox.2009.05.008.CrossRefPubMed Ohba T, Kometani T, Shoji F, Yano T, Yoshino I, Taguchi K, Kuraoka I, Oda S, Maehara Y: Expression of an X-family DNA polymerase, pol lambda, in the respiratory epithelium of non-small cell lung cancer patients with habitual smoking. Mutat Res. 2009, 677: 66-71. 10.1016/j.mrgentox.2009.05.008.CrossRefPubMed
21.
go back to reference Sobin LH, Hermanek P, Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988, 61: 2310-2314. 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X.CrossRefPubMed Sobin LH, Hermanek P, Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 1988, 61: 2310-2314. 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X.CrossRefPubMed
22.
go back to reference Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC: Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011, 91: 887-893. 10.1016/j.athoracsur.2010.11.011.CrossRefPubMed Wang BY, Goan YG, Hsu PK, Hsu WH, Wu YC: Tumor length as a prognostic factor in esophageal squamous cell carcinoma. Ann Thorac Surg. 2011, 91: 887-893. 10.1016/j.athoracsur.2010.11.011.CrossRefPubMed
23.
go back to reference Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM: Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002, 95: 1434-1443. 10.1002/cncr.10868.CrossRefPubMed Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM: Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002, 95: 1434-1443. 10.1002/cncr.10868.CrossRefPubMed
24.
go back to reference Willett CG, Warland G, Coen J, Shellito PC, Compton CC: Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. Int J Radiat Oncol Biol Phys. 1995, 32: 57-61. 10.1016/0360-3016(94)00457-V.CrossRefPubMed Willett CG, Warland G, Coen J, Shellito PC, Compton CC: Rectal cancer: the influence of tumor proliferation on response to preoperative irradiation. Int J Radiat Oncol Biol Phys. 1995, 32: 57-61. 10.1016/0360-3016(94)00457-V.CrossRefPubMed
25.
go back to reference Turkyilmaz A, Eroglu A, Subasi M, Karaoglanoglu N: Clinicopathological features and prognosis of esophageal cancer in young patients. Is there a difference in outcome?. Dis Esophagus. 2009, 22: 211-215. 10.1111/j.1442-2050.2008.00890.x.CrossRefPubMed Turkyilmaz A, Eroglu A, Subasi M, Karaoglanoglu N: Clinicopathological features and prognosis of esophageal cancer in young patients. Is there a difference in outcome?. Dis Esophagus. 2009, 22: 211-215. 10.1111/j.1442-2050.2008.00890.x.CrossRefPubMed
26.
go back to reference Lin MY, Chen MC, Wu IC, Wu DC, Cheng YJ, Wu CC, Chai CY, Lee JM, Wu MT: Areca users in combination with tobacco and alcohol use are associated with younger age of diagnosed esophageal cancer in Taiwanese men. PLoS One. 2011, 6: e25347-10.1371/journal.pone.0025347.PubMedCentralCrossRefPubMed Lin MY, Chen MC, Wu IC, Wu DC, Cheng YJ, Wu CC, Chai CY, Lee JM, Wu MT: Areca users in combination with tobacco and alcohol use are associated with younger age of diagnosed esophageal cancer in Taiwanese men. PLoS One. 2011, 6: e25347-10.1371/journal.pone.0025347.PubMedCentralCrossRefPubMed
Metadata
Title
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
Authors
Ren-Wen Huang
Yin-Kai Chao
Yu-Wen Wen
Hsien-Kun Chang
Chen-Kan Tseng
Sheng-Chieh Chan
Yun-Hen Liu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-170

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue